ExpreS2ion to Participate in Key Investor Event in January 2026
Hørsholm, Denmark, 19 January 2026 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in an upcoming investor event in January 2026, the Redeye Thematic Event: Fight Cancer.
These events represent important opportunities to showcase ExpreS2ion’s innovative technology platform and exciting development pipeline to scientific and investment audiences. More details, including event registration information, are available on the Company’s website and via the links below. To arrange a meeting at these events, please contact us at partnering@expres2ionbio.com or investor@expres2ionbio.com.
21 January 2026 | Redeye Theme: Fight Cancer
Stockholm, Sweden and virtual
ExpreS2ion will participate in Redeye Theme: Fight Cancer 2026, a focused life sciences investor event highlighting Nordic companies active in oncology and cancer-related innovation. CFO Keith Alexander will present ExpreS2ion at 10:50 CET, sharing updates on the company’s cancer vaccine programs and strategic priorities. For more details about the event, including how participate in person or stream the presentation, see the official event page.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.